The effectiveness and risks of programming an insulin pump to counteract the dawn phenomenon in type 1 diabetes

Endocrine Practice

Volumn 20, Issue 12, 2014, Pages 1290-1296

  Bouchonville, Matthew F ^a   Jaghab, Justin J ^a   Duran Valdez, Elizabeth ^a   Schrader, Ronald M ^b   Schade, David S ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN DETEMIR; INSULIN GLARGINE;

ADULT; ARTICLE; BLOOD GLUCOSE METER; BLOOD GLUCOSE MONITORING; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTINUOUS INFUSION; CONTINUOUS SUBCUTANEOUS INSULIN INFUSION PROGRAMMING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC PATIENT; EVENING DOSAGE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INSULIN TREATMENT; LONGITUDINAL STUDY; MALE; MEAL; OBSERVATIONAL STUDY; PREDICTION; REPRODUCIBILITY; RISK ASSESSMENT;

EID: 84920007347     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP144198.OR     Document Type: Article

References (31)

1. Carroll MF, Schade DS. The dawn phenomenon revisited: implications for diabetes therapy. Endocr Pract. 2005;11: 55-64.
2. Bending JJ, Pickup JC, Collins AC, Keen H. Rarity of a marked "dawn phenomenon" in diabetic subjects treated by continuous subcutaneous insulin infusion. Diabetes Care. 1985;8:28-33.
3. Koivisto VA, Yki-J?rvinen H, Helve E, Karonen SL, Pelkonen R. Pathogenesis and prevention of the dawn phenomenon in diabetic patients treated with CSII. Diabetes. 1986;35:78-82.
4. Schmidt MI, Hadji-Georgopulos A, Rendell M, Margolis S, Kowarski A. The dawn phenomenon, an early morning glucose rise: implications for diabetic intraday blood glucose variation. Diabetes Care. 1981;4:579-585.
5. Carroll MF, Hardy KJ, Burge MR, Schade DS. Frequency of the dawn phenomenon in type 2 diabetes: implications for diabetes therapy. Diabetes Technol Ther. 2002;4:595-605.
6. Kobayashi K, Ameniya S, Sawanobori E, et al. Role of IGF binding protein-1 in the dawn phenomenon and glycemic control in children and adolescents with IDDM. Diabetes Care. 1997;20:1442-1447.
7. Atiea JA, Luzio S, Owens DR. The dawn phenomenon and diabetes control in treated NIDDM and IDDM patients. Diabetes Res Clin Pract. 1992;16:183-190.
8. Perriello G, De Feo P, Torlone E, et al. The dawn phenomenon in type 1 (insulin-dependent) diabetes mellitus: magnitude, frequency, variability, and dependency on glucose counterregulation and insulin sensitivity. Diabetologia. 1991;34:21-28.
9. Ludvigsson J, Hanas R. Continuous subcutaneous glucose monitoring improved metabolic control in pediatric patients with type 1 diabetes: a controlled crossover study. Pediatrics. 2003;111:933-938.
10. Edge JA, Matthews DR, Dunger DB. The dawn phenomenon is related to overnight growth hormone release in adolescent diabetics. Clin Endocrinol (Oxf). 1990;33:729-737.
11. Stephenson JM, Schernthaner G. Dawn phenomenon and Somogyi effect in IDDM. Diabetes Care. 1989;12:245-251.
12. Atiea JA, Vora JP, Owens DR, et al. Non-insulindependent diabetic patients (NIDDMs) do not demonstrate the dawn phenomenon at presentation. Diabetes Res Clin Pract. 1988;5:37-44.
13. Atiea JA, Ryder RR, Vora J, et al. Dawn phenomenon: its frequency in non-insulin-independent diabetic patients on conventional therapy. Diabetes Care. 1987;10:461-465.
14. Havlin CE, Cryer PE. Nocturnal hypoglycemia does not commonly result in major morning hyperglycemia in patients with diabetes mellitus. Diabetes Care. 1987;10: 141-147.
15. Bolli GB, Gerich JE. The "dawn phenomenon"-A common occurrence in both non-insulin-dependent and insulin-dependent diabetes mellitus. N Engl J Med. 1984; 310: 746-750.
16. Hiar C. Clinical Performance of the DCA 2000+ Hemoglobin A1c System Six-Minute Assay. Bayer Diagnostics Division, Tarrytown, NY, 1998.
17. SAS Institute Inc. Base SAS® 9.3 Procedures Guide. Cary, NC: SAS Institute Inc, 2011.
18. King AB, Clark D, Wolfe GS. Contribution of the dawn phenomenon to the fasting and postbreakfast hyperglycemia in type 1 diabetes treated with once-nightly insulin glargine. Endocr Pract. 2012;18:558-562.
19. Monnier L, Colette C, Dejager S, Owens D. Magnitude of the dawn phenomenon and its impact on the overall glucose exposure in type 2 diabetes: is this of concern? Diabetes Care. 2013;36:4057-4062.
20. Monnier L, Colette C, Sardinoux M, Baptista G, Regnier-Zerbib A, Owens D. Frequency and severity of the dawn phenomenon in type 2 diabetes: relationship to age. Diabetes Care. 2012;35:2597-2599.
21. Porcellati F, Lucidi P, Bolli GB, Fanelli CG. Thirty years of research on the dawn phenomenon: lessons to optimize blood glucose control in diabetes. Diabetes Care. 2013;36: 3860-3862.
22. Papargyri P, Ojeda Rodríguez S, Corrales Hernández JJ, et al. An observational 7-year study of continuous subcutaneous insulin infusion for the treatment of type 1 diabetes mellitus. Endocrinol Nutr. 2014;61:141-146.
23. Hovorka R, Allen JM, Elleri D, et al. Manual closedloop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial. Lancet. 2010;375:743-751.
24. Phillip M, Battelino T, Atlas E, et al. Nocturnal glucose control with an artificial pancreas at a diabetes camp. N Engl J Med. 2013;368:824-833.
25. Bergenstal RM, Klonoff DC, Garg SK, et al. Thresholdbased insulin pump interruption for reduction of hypoglycemia. N Engl J Med. 2013;369:224-232.
26. Trümper BG, Reschke K, Molling J. Circadian variation of insulin requirement in insulin dependent diabetes mellitus: the relationship between circadian change in insulin demand and diurnal patterns of growth hormone, cortisol and glucagon during euglycemia. Horm Metab Res. 1995; 27:141-147.
27. Beaufrère B, Beylot M, Metz C, et al. Dawn phenomenon in type 1 (insulin-dependent) diabetic adolescents: influence of nocturnal growth hormone secretion. Diabetologia. 1988;31:607-611.
28. Kerner W, Navascués I, Torres AA, Pfeiffer EF. Studies on the pathogenesis of the dawn phenomenon in insulin-dependent diabetic patients. Metabolism. 1984;33: 458-464.
29. Perriello G, De Feo P, Torlone E, et al. Nocturnal spikes of growth hormone secretion cause the dawn phenomenon in type 1 (insulin-dependent) diabetes mellitus by decreasing hepatic (and extrahepatic) sensitivity to insulin in the absence of insulin waning. Diabetologia. 1990;33:52-59.
30. Campbell PJ, Bolli GB, Cryer PE, Gerich JE. Pathogenesis of the dawn phenomenon in patients with insulin-dependent diabetes mellitus. Accelerated glucose production and impaired glucose utilization due to nocturnal surges in growth hormone secretion. N Engl J Med. 1985;312:1473-1479.
31. Shih KC, Hsieh SH, Kwok CF, Hwu CM, Hsieh PS, Ho LT. Effect of growth hormone on dawn phenomenon in patients with type 2 diabetes. Growth Factors. 2013;31: 66-73.